Merck announces MS research scholarship
01 June, 2017Merck has announced further support for Australia's Multiple Sclerosis (MS) community with a new research scholarship to help fund neurology research at the Royal Melbourne Hospital.
Researchers discover inflammatory 'dimmer switch'
26 May, 2017 by Adam FloranceMonash University researchers have uncovered how a group of proteins perform like a 'dimmer switch', causing inflammation ranging from acute to chronic. The findings could contribute to new treatments for inflammatory diseases including type 2 diabetes, atherosclerosis, heart attack and stroke.
Australia, Japan team up for advanced cancer treatment
25 May, 2017ANSTO, the Centre for Medical Radiation Physics at the University of Wollongong and the National Institute of Radiological Sciences (NIRS), Japan, have partnered to deliver advanced cancer treatment, based on carbon ion therapy.
Preventing excessive platelet production in diabetics
23 May, 2017Researchers have uncovered a novel mechanism behind excessive platelet production present in people with diabetes, placing them at increased risk of cardiovascular complications such as heart attack and stroke.
Weeding out malaria
19 May, 2017 by Adam FloranceThe Menzies School of Health Research recommends a two-stage treatment for the notoriously difficult-to-cure Plasmodium vivax malaria, which has a similar approach to removing weeds from a garden bed.
Australian researchers make melanoma breakthrough
19 May, 2017Australian researchers have achieved a major breakthrough in the fight against advanced melanoma, giving hope to over 1800 Australians expected to die from the deadly disease this year.
Promoting next-gen cancer research
18 May, 2017Leaders from the Australian Nuclear Science and Technology Organisation (ANSTO), experts from Italy and clinicians from NSW recently met to explore how the full range of particle therapy treatments may be made available to Australians.
PharmAust secures non-cancer patent
17 May, 2017Australian-listed, clinical-stage oncology company PharmAust has secured a new patent in Australia covering the use of its lead drug for non-cancer applications, including neurodegenerative diseases, diabetes and age-related disorders.
'Tumour-trained' immune cells move from one tumour to another
16 May, 2017Scientists at Sydney's Garvan Institute of Medical Research have discovered that 'tumour-trained' immune cells — which have the potential to kill cancer cells — move from one tumour to another.
Immunotherapy may increase tumour growth in some cases
16 May, 2017Scientists have found that cancer immunotherapy, intended to boost the body's immune system in order to fight tumours, may actually be having the opposite effect in some cancers.
Avita Medical files IPR against Renovacare patent
12 May, 2017Avita Medical Limited, a regenerative medicine company focused on the treatment of wounds and skin defects, has filed an Inter Partes Review (IPR) petition against Renovacare patent.
Do painkillers cause heart attacks?
12 May, 2017 by Adam FloranceThe latest research from Canada has found that regular use of even small amounts of over-the-counter painkillers can rapidly increase the risk of heart attack, but local experts suggest that the benefits can outweigh the risks in many cases.
Key China patent for PharmAust
08 May, 2017PharmAust, an ASX-listed oncology company, has secured a key China patent.
Australian researchers find unexpected genomic landscape in melanoma
05 May, 2017Genetic changes in acral and mucosal melanomas are completely different to the mutations found in skin melanoma, reveals a new study by Australian researchers.
New mechanism for autoimmune diseases
05 May, 2017 by Adam FloranceResearchers from Monash University have "answered one of the biggest questions in autoimmune disease" by determining the mechanism underlying the key genetic risk factors that lead to a raft of autoimmune diseases including: Crohn's disease, multiple sclerosis, type 1 diabetes, ulcerative colitis, rheumatoid arthritis and various forms of kidney disease.
